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Running title: Unmet needs in CV management of IJD 
Abstract  
Introduction: Increased cardiovascular (CV) morbidity and mortality is observed in 
inflammatory joint diseases (IJDs) such as rheumatoid arthritis, ankylosing spondylitis 
and psoriatic arthritis. However, the management of CV disease in these conditions is 
far from being well established. 
Areas covered: This review summarizes the main epidemiologic, pathophysiological 
and clinical risk factors of CV disease associated with IJDs. Less common aspects on 
early diagnosis and risk stratification of the CV disease in these conditions are also 
discussed. In Europe, the most commonly used risk algorithm in patients with IJDs is 
the modified SCORE index based on the revised recommendations proposed by the 
EULAR task force in 2017. 
Expert opinion: Early identification of IJD patients at high risk of CV disease is 
essential. It should include the use of complementary non-invasive imaging 
techniques. A multidisciplinary approach aimed to improve heart-healthy habits, 
including strict control of classic CV risk factors is crucial. Adequate management of 
the underlying IJD is also of main importance since reduction of disease activity 
decreases the risk of CV events. Non-steroidal anti-inflammatory drugs may have a 
lesser harmful effect in IJD than in the general population, due to their anti-
inflammatory effects along with other potential beneficial effects. 
 
Keywords: ankylosing spondylitis, cardiovascular disease, cardiovascular risk factors, 









Unmet needs in CV management of IJD  Exp Rev Clin Immunol 
3 
 
Information Classification: General 
 
Article Highlights 
 The prevalence of CV morbidity and mortality in IJDs is increased compared to 
that in general population. 
 Besides genetics, traditional CVRFs and those related to the inflammatory 
disease, there are other psychosocial and emergent factors that can negatively 
influence the occurrence of CVD events in patients with IJD. 
 Current risk chart algorithms used to determine the CV risk of the general 
population usually underestimate the actual CV risk of patients with IJD. 
 The EULAR task force recommends calculating the CV risk of patients with 
RA by multiplying the risk obtained using CV risk charts by 1.5. The applied 
model may be possibly extrapolated to other IJDs. 
 Strict adherence to national and international guidelines for CV risk 
management is recommended, especially regarding the control of traditional 
CVRFs, for the prevention of new CV events. 
 The 2019 recommendations for the management of dyslipidemias focused on 
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1. Introduction  
The term inflammatory joint diseases (IJD) encompasses a group of chronic 
inflammatory diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS) 
and psoriatic arthritis (PsA). IJD mainly affect the joints of the axial or peripheral 
skeleton and are associated with a wide spectrum of extra-articular manifestations that 
depend on the type of disease. They also share a set of common comorbidities, 
predominantly cardiovascular (CV), mood disorders (anxiety and depression), 
infection, cancer, bone loss, and liver, gastrointestinal and kidney alterations [1,2*-4]. 
RA is a chronic systemic autoimmune and inflammatory disease which 
characteristically affects diartrodial synovial joints leading to joint damage and 
physical disability [5*]. AS is included in the group of spondyloarthritis (SpA) that 
also comprises forms of atypical AS without radiographic manifestations (non-Rx 
SpA), reactive arthritis, PsA and other arthropathies associated to inflammatory bowel 
disease. PsA is characterized by synovial and entheseal inflammation and psoriasis. 
The clinical presentation of joint disease in PsA is heterogeneous and can vary from 
peripheral arthritis to asymmetrical oligoarthritis or axial forms similar to AS. 
Cardiovascular comorbidity is by far the most significant morbidity in these 
conditions, due to its frequency and impact on patient’s survival and quality of life. In 
fact, subclinical CV disease (CVD), CV events (CVE) and mortality are increased in 
IJD, as a consequence of a common process of endothelial damage and accelerated 
atherosclerosis [6-8,9**]. The excess of CV morbidity observed in these patients 
[10,11] is the result of a combined effect of traditional CV risk factors (CVRFs), 
chronic inflammation
 
and a genetic component that has more extensively been studied 
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CV disease and CV comorbidity, due to the amount and quality of information on this 
issue. For this reason, RA will serve as the guide disease for this revision.  
In this review we will focus on both well-known aspects of the CV disease in IJD, 
more specifically RA, AS and PsA, and those features that require further research as 
well as in the “unmet needs” in this field nowadays. 
2. Areas covered 
2.1. Epidemiology of cardiovascular disease in IJD  
The risk of atherosclerotic CVD in IJD, in particular in RA, AS and PsA is increased 
compared to the general population [9**,11,12*]. In a cross-sectional study conducted 
in Spain, the prevalence of CVD in a cohort of IJD was increased compared to a cohort 
of non-inflammatory subjects [15]. Mortality due to CVD in IJD is also increased 
when compared to the general population [9**]. 
More specifically, the risk of CVD in RA is comparable to that of type 2 diabetes 
mellitus (DM2), which translates into an increase in premature mortality due to CV 
events [10,11,12*,16]. A meta-analysis made a few years ago showed that CV 
mortality in patients with RA was 50% higher than in the general population, with an 
increase in coronary disease of 59% and an increase in cerebrovascular events of 52% 
[11]. Quite similar results were obtained in another study by the same authors: 68% of 
acute myocardial infarction (MI) and 41% of strokes [10], which were equivalent to 
those found in a population without RA but 10 to 15 years older. 
CV morbidity and mortality are also increased in AS and PsA [9**,12*]. Several 
studies have shown an increase in the prevalence of coronary heart disease (CHD), 
stroke and peripheral arterial disease (PAD) in patients with AS and PsA with respect 
to the general population [9**,12*,17]. A meta-analysis confirmed an increase of MI 
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patients with AS with respect to the general population [18]. PsA also seems to exhibit 
similar CV risk, although its estimates are more difficult to determine due to the bias 
related to the cutaneous involvement of the disease. In a cross-sectional study that 
compared non-fatal CV events in RA and PsA, the prevalence found was very similar 
in both entities: 10% in PsA vs. 12.4% in RA [19]. 
Finally, it is important to point out that the clinical manifestations of CVD in patients 
with IJD, particularly in relation to coronary events, are usually different from the 
general population. They frequently start with a silent ischemia, often attributed to 
mechanical pain of the thoracic wall, which frequently causes diagnostic delays of 
their heart disease and higher mortality [12*]. 
2.2. Subclinical atherosclerosis in IJD  
Subclinical CVD in patients with IJD can be detected years before the clinic appears, 
using different non-invasive methods [20*,21**,22]. Nowadays, there are several 
methods available for evaluating subclinical atherosclerosis in these patients (Table 1). 
2.2.1. Assessment of endothelial dysfunction 
Endothelial dysfunction and arterial stiffness are recognized as surrogate 
measurements of CVD [6,7]. Arterial stiffness can enhance CV risk by increasing 
atherogenesis or adverse hemodynamic effects. Arterial stiffness is most commonly 
assessed by aortic pulse wave velocity and augmentation index. Indeed, patients with 
IJD exhibit increased arterial stiffness [22]. Alternative measures of arterial stiffness 
include aortic distensibility, and the ankle-brachial elasticity index (ABI), measured 
using high-sensitivity brachial ultrasonography. Since these methods are laborious and 
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2.2.2. Carotid ultrasound 
Ultrasound (US) is possibly the most simple and useful non-invasive surrogate marker 
of CVD from a practical point of view. Carotid US provides accurate and reproducible 
measurements of anatomical structures without harmful ionizing radiation. The two 
most commonly used measurements by US are the carotid artery intima-media wall 
thickness (cIMT) and the presence of atheroma plaques into the carotids. Both 
parameters have shown to be good predictors of CV events in patients with RA 
[23,24]. Several systematic literature search and meta-analysis have confirmed 
increased cIMT and greater presence of carotid plaques in patients with RA vs. 
controls [25, 26*].  
Interestingly, US allows reclassifying the CV risk of IJD patients considered as 
intermediate or moderate CV risk through clinical scores in high or very high risk. In 
fact, an abnormally high incidence of carotid plaques was found in patients with RA 
that had been categorized as having moderate risk by application of the Systematic 
COronary Risk Evaluation (SCORE) scale [27**,28]. Similar findings have also been 
observed in patients with AS and PsA without additional factors of CV risk [29-31]. 
As observed in RA, patients with AS and PsA also had higher cIMT than matched 
controls [31-33]. In AS, other abnormal carotid US findings associated with 
subclinical atherosclerosis, such as higher frequency of plaques than matched controls 
[32], have also been reported. 
Since carotid US is a simple, cheap and reproducible method, it is the most widely 
used method in the rheumatologic setting. In practical terms, patients with cIMT ≥ 0.9 
mm are included in the category of high/very high CV risk [34*,35]. More 
interestingly, the presence of carotid plaques reclassifies a patient into the category of 
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Moreover, carotid US is a good method to determine progression of atherosclerotic 
disease in patients with IJD. In these patients the CV risk increases proportionally with 
the number of plaques and it is greater when plaques are bilateral.  
2.2.3. Computed tomography (CT) 
CT can be used for evaluating the burden of coronary artery calcification (CAC) or for 
anatomical visualization of coronary arteries by CT coronary angiography (CTCA), 
being CAC score a good measure of premature atherosclerosis. Both, the American 
College of Cardiology (ACC) and the European Society of Cardiology (ESC) 
recommend the use of CAC score to monitor risk assessment when CV risk is unclear 
using traditional CVD risk algorithms [36,37]. CAC is also a good predictor of CVE in 
patients with RA and other autoimmune diseases. Indeed, it was found to be more 
sensitive than classic risk chart algorithms to identify high-CV risk RA patients [28].   
2.2.4. Positron emission tomography 
Positron emission tomography (PET) myocardial perfusion imaging detects uptake of 
positron-emitting radiotracers in the heart and perfusion of blood into the myocardium.   
PET has shown to predict CV mortality in patients with coronary artery disease [38], 
and it could potentially be applied to the CV risk stratification of high-risk patient 
groups such as those with IJD. Limitations of PET include its price, availability of 
tracers, use of ionizing radiation and limited assessment of cardiac structures [21**]. 
2.2.5. Cardiovascular magnetic resonance 
Cardiovascular magnetic resonance (CMR) provides detailed information on the 
structure and composition of myocardium allowing the detection of a wide variety of 
myocardial diseases. It is useful for the quantitative evaluation of left and right 
ventricular volumes, mass and function, cardiac tissue characterization and assessment 
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autoimmune diseases [39]. The main limitations of CMR include price, its availability 
and general intrinsic contraindications to magnetic resonance [21**,39]. Chronic 
myocardial ischemia can be assessed using myocardial perfusion at rest and during 
pharmacological vasodilator stress [40*].  
Taken all this into account, the ideal imaging technique in the assessment of CVD risk 
in IJD patients should be cheap, safe, reproducible, able to detect early subclinical 
disease, predict CV mortality, identify high-CV risk patients and assess the specific 
response to therapies. Although there is no unanimous consensus, we believe that 
carotid US is currently the best technique to be used in the daily clinical practice 
(Table 1).  
2.3. Inflammation and atherosclerosis  
Inflammation plays an important role in the pathogenesis of atherosclerosis and CVD 
both in inflammatory rheumatic diseases [41-43**,44**] and in the general population 
[45**]. In fact, it contributes to all stages of atherosclerosis, from plaque formation to 
plaque instability and eventual plaque rupture with its important consequences [43**]. 
Abnormality of acute phase reactants has been found to be associated with subclinical 
atherosclerosis and greater CV morbi-mortality in patients with RA [46]. Of note, C-
reactive protein (CRP) level is an independent predictor of CV risk, particularly of MI, 
in the general population [47]. Notably, higher IL-6 levels are also associated with 
increased mortality in patients with acute coronary syndromes (ACS) and with 
increased risk of MI in healthy men [48,49]. 
Interestingly, chronic inflammation causes an alteration in the lipid profile of patients 
with IJD. It leads to a reduction of serum total cholesterol (TC), LDL-cholesterol 
(LDL-C) and HDL-cholesterol (HDL-C) levels. However, this quantitative reduction is 
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atherogenic properties [50]. Furthermore, lipoprotein (a) (Lp(a)) is also an important 
promoter of atherogenesis. When oxidized, it can provoke an immune response similar 
to that of oxidized LDL, and increases in Lp(a) levels have been associated with 
inflammation [51]. Thus, Lp(a) is an independent risk factor for CVD that may be 
augmented in RA [51]. 
To determine if the reduction of the inflammatory burden without affecting lipid levels 
may reduce the risk of CVD, Ridker et al performed a randomized, double-blind trial 
of canakinumab, a monoclonal antibody targeting interleukin-1β, in a large series of 
patients with previous myocardial infarction who had high-sensitivity C-reactive 
protein level ≥ 2 mg/L. Although this biologic agent did not reduce the lipid levels 
when compared with baseline results, at a median follow-up of 3.7 years, patients 
treated with canakinumab at a dose of 150 mg subcutaneously every 3 months had a 
significantly lower rate of recurrent CVE when compared with those receiving placebo 
[52*]. Interestingly, this effect was independent of any lipid-level lowering. These 
findings highlight the pivotal effect of inflammation in the development of CVD in the 
general population. The results also suggest that the blockade of inflammatory 
pathways may reduce the risk of CVD in the general population. It may also more 
relevant in patients with IJDs since these individuals have a chronic inflammation 
status. 
A crucial aspect with major clinical relevance in patients with high inflammatory 
burden is the increased risk of vulnerability and rupture of atherosclerotic plaques 
[12*,13]. In a post-mortem study, 48% of plaques of patients with RA were classified 
as unstable by histologic criteria compared with 22% in non-RA controls. 
Additionally, inflammation in the coronary artery wall was more prominent in subjects 









Unmet needs in CV management of IJD  Exp Rev Clin Immunol 
11 
 
Information Classification: General 
carotid US comparing patients with RA and controls, active RA patients had lower 
grey-scale plaque values, a typical characteristic of vulnerability and rupture of 
plaques linked to atherothrombosis [13,54*]. 
Adipokines are cytokines secreted by adipose tissue. In patients with IJD there is a 
dysregulated secretion of these molecules due to adipose tissue dysfunction. In fact, it 
can contribute to the pathogenesis of atherosclerotic disease in this population. In 
patients with severe RA undergoing anti-TNF-therapy high-grade inflammation 
negative and independently correlated with circulating adiponectin concentrations 
whereas low adiponectin levels clustered with metabolic syndrome (MetS) features 
[55]. Adiponectin levels negatively correlated with triglycerides/HDL-C ratios, 
TC/HDL-C ratios and high fasting plasma glucose levels, independently of CRP levels 
and the body mass index (BMI) [55]. Furthermore, a strong association between 
laboratory markers of inflammation, particularly CRP and resistin levels was found in 
patients with severe RA undergoing anti-TNF therapy [56]. Also, a positive correlation 
between BMI and serum level of leptin was found in these patients.  
As in RA, inflammation in SpA also plays a pivotal role in all phases of formation and 
development of atheroma plaques, intensifying the effects of conventional risk factors. 
An important role of adipokine production in the inflammation and development of 
atherosclerosis has been found in SpA, particularly in PsA [57]. As previously 
discussed, an increase in the prevalence of MetS has been documented in patients with 
IJD [2*], particularly in those with PsA [58*,59]. 
In summary, inflammation has an important contribution to the development of CVD 
in patients with IJD. Using heart failure (HF) as an example, it has been calculated that 
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risk among RA patients, suggesting that mechanisms associated with inflammation are 
of major importance in these patients [60*].  
2.4. Traditional CV risk factors 
Traditional CVRFs, such as smoking, DM, obesity, hypertension (HTN) and 
dyslipidemia are independently associated with subclinical atherosclerosis, CVE and 
increased mortality in patients with IJD [12*,61-63].  
Smoking is known to be a risk factor for the development of RA, particularly in 
rheumatoid factor (RF) and anti-CCP positive RA patients. A recent meta-analysis 
showed an increased prevalence of cigarette smoking in patients with RA (OR 1.56, 
95% CI 1.34, 1.80) [64]. Other studies also found a higher prevalence of current and 
past smokers among patients with RA compared to controls [11].    
Although there are contradictory data in the literature, DM appears to be more 
common in RA patients than in controls. In this regard, insulin resistance (IR) and 
MetS are increased in patients with PsA and RA [58*,59,65]. Interestingly, some anti-
rheumatic medications such as some anti-tumor necrosis factor (TNF)-α monoclonal 
antibodies and anti-interleukin (IL)-6 tocilizumab exert a positive effect on IR in 
patients with RA and AS [66,67]. Likewise, hydroxychloroquine (HCQ), and 
methotrexate (MTX) may also reduce the risk of DM in RA patients.  
Obesity itself contributes to a low-grade inflammation status, as adipose tissue is a 
major organ producer of pro-inflammatory cytokines. A high BMI is associated with 
elevated CRP levels and increased risk of CVD in the general population [68]. 
Abnormal body fat composition in RA and PsA is also associated with higher CRP 
levels and more severe disease [69]. However, severe and advanced disease in patients 
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loss, leading in extreme cases to a state of cachexia which also causes an increased risk 
CV. 
HTN has frequently been found in patients with RA. Whereas some studies highlight 
HTN as an important risk factor for CVD in RA patients [61,62,70], others found 
similar prevalence of HTN in RA and in controls [71]. Nevertheless, HTN is 
frequently underdiagnosed in young people with IJD or undertreated in elderly patients 
[72]. In AS and PsA, HTN was found in 26% and 29.5% of patients, respectively [15].  
The issue of lipids deserves a separate mention as independent CV risk factor in IJD. 
As already mentioned, and although the levels of total CT, LDL and HDL-C decrease 
during active phases of disease, the CV risk continues increasing [12*,73*]. Since in 
patients with active disease the decrease in the HDL-C fraction is more marked, it is 
advisable to assess the CT/HDL-C ratio or “atherogenic index” (AI) instead of CT. In 
this regard, the most adequate time to evaluate the lipid profile in patients with IJD is 
when the disease is in remission or with low activity since CT levels increase in the 
phases of inactivity or under the effects of treatment. Lipid abnormalities are also 
common in PsA with lower serum levels of HDL-C and higher serum levels of 
triglycerides [57,74]. Dyslipidemia is more prominent in PsA patients with active 
disease, suggesting a link between inflammation and the lipid profile [74,75]. Low 
total CT levels have also been reported in AS [76]. As with HTN, dyslipidemia is 
underdiagnosed and often undertreated in patients with IJD, which can worsen the 
course and prognosis of this comorbidity [77,78].  
Finally, it is important to remark that the effect of traditional CVRF on the vascular 
tree may be more harmful in patients with IJD than in the general population, because 
classic CV risk factors amplify the harmful effect that chronic inflammation produces 
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2.5. Genetics as a contributor to CV risk in IJD 
Genetics, together with inflammation and traditional CVRF, constitutes the third basic 
component associated with an increased CV risk in patients with IJD (Figure 1). 
Family history of premature CVE in a first-degree relative -before 55 years in men and 
before 65 years in women- raises significantly the risk of CVD in inflammatory 
patients and in the general population [79*].  
There are a number of genetic studies on CVD in patients with IJD, particularly in 
patients with RA. Among them, the most interesting data regarding CVD risk are 
found in the genes of the human leukocyte antigen (HLA) region in patients with RA. 
HLA is also the main genetic factor implicated in inflammatory immune-mediated 
pathologies and it is associated with more diseases than any other region of the human 
genome [80*].  
Other genetic polymorphisms of genes implicated in different inflammatory and 
metabolic pathways, located inside and outside the HLA region, appears to increase 
the augmented risk of CVD in patients with RA [81-85].  
2.6. Anxiety, depression, renal failure and other emergent CV risk factors (Table 2) 
Anxiety and depression are well known factors associated with CV risk, although 
sparsely weighted in the current guidelines and CV risk scales. Recent meta-analyses 
proved that both depression and anxiety are independently associated with incident 
CVE rates [86,87]. Anxiety can increase CVD risk through decreased adherence to 
healthy behaviors as well as physiological mechanisms including autonomic 
dysfunction, inflammation, endothelial dysfunction and increased platelet aggregation 
[88**]. The prevalence of depression and anxiety is increased in RA patients from 
high income countries [89,90]. They also predict long-term physical health outcomes 
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(anger, hostility, type D personality, etc.), especially when persistent, are associated 
with an increase in CVD and mortality [92**]. On the other hand, low socioeconomic 
class individuals, lack of social support, stress at work and/or family life have a 
negative influence on patients with known CVD [93**] (Table 2). 
The link between periodontal disease and CVD in the general population is also well-
recognized. Although the cause-effect relationship is not well understood, there is a 
suspicion that periodontal bacteria may play a pathogenic role in CVD [94*]. Chronic 
kidney disease (CKD) was associated with myocardial infarction and fatal coronary 
heart disease in black, but not in white Americans [95]. Even mildly reduced estimated 
glomerular filtration rate increases the risk of incident atherosclerotic CVD [96]. 
Moreover, RA enhances the incidence of CKD. In a cohort study of African RA 
patients, the estimated glomerular filtration rate (CKD-EPI eGFR) was lower than 90 
ml/min/1.73m
2
 in 49.1% of blacks and 30.6% of white participants, respectively [97]. 
Using receiver operator characteristic (ROC) curve analysis, the CKD-EPI eGFR 
predicted the presence of carotid artery plaque among black RA patients [97]. In fact, a 
CKD-EPI eGFR lower than 82 ml/min/1.73m2 was associated with a 2.22-fold 
increased prevalence of carotid plaque in black African RA patients [97]. In 
consequence, in patients with IJD, periodic monitoring of microalbuminuria and 
proteinuria are recommended because they may help to quantify the organ damage 
degree secondary to vascular injury.  
Low levels of vitamin D have been found in several cohorts of patients with different 
IJD [98,99]. Several studies have demonstrated the beneficial effect of vitamin D in 
the control of HTN and CV risk and low levels of vitamin D have been associated with 
greater CV morbidity [100].  
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The use of non-steroidal anti-inflammatory drugs (NSAIDs), including coxibs, has 
been associated with an increased risk of CV mortality [101]. Nevertheless, a 
longitudinal cohort study of 17,320 patients with RA followed-up for 5-years average 
showed a modest increase of CV risk, smaller than that observed in the general 
population [102]. Whereas NSAIDs exposure was associated with a 22% of risk 
increase in patients with RA, the risk following NSAIDs exposure was around 50% in 
non-RA patients [102]. A possible explanation for this finding might be related to the 
beneficial effect that NSAIDs confer on the mobility, which would counteract its direct 
harmful effect on the CV system. However, it seems prudent to minimize their use, 
especially in patients with a high CV risk and HTN associated. 
We must take special attention to the combined use of NSAIDs and aspirin due to the 
increased risk of gastrointestinal complications. Besides, some NSAIDs appear to 
attenuate the antiplatelet effects of aspirin. However, coxibs do not seem to interact 
with the anti-platelet effects of aspirin. Thus, when a combination of NSAIDs and 
aspirin is necessary, celexocib -a coxib with a relatively low CV toxicity- might be a 
reasonable alternative. 
Glucocorticoids (GC) exhibit a complex effect on the vascular system. While short-
term at low doses GC do not appear to be harmful and even may be beneficial for the 
vasculature due to the reduction in inflammation and the improvement in patient 
mobility, high doses of GC, especially when maintained for long-term, can promote 
atherosclerosis and increase CV risk.  
In a study of 50,238 person-years in 8,384 RA patients, including 298 cases with MI, 
current use of GCs was associated with a 68% increased risk of MI in multivariable 
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all associated with a significant increased risk of MI [103]. By contrast, GC use was 
not associated with an increased risk of CVE in another study [104].  
There is a general agreement on the fact that both synthetic DMARDs and biologic 
therapies aimed to reduce and control disease activity can attenuate atherosclerosis by 
reducing the systemic inflammatory burden. In fact, available data indicate that anti-
TNF, MTX and HCQ may reduce the CV risk [105,106]. The potential beneficial 
effect on CVD of other biological therapies is less known. Nonetheless, adequate 
control of disease activity would reduce the need of using NSAIDs and GC, which 
would eventually help reduce the incidence of new CVE in these patients.  
2.8. Stratification of CV risk in patients with inflammatory joint di eases  
In order to identify subjects at risk of developing CVE, it is critical to carry out an 
adequate stratification of the CV risk of patients with IJD. This was classically 
performed by using scales or risk chart algorithms [21**,79*,107*]. Currently, there 
are several scales available that are extrapolated from those designed for the general 
population. The best known are the SCORE, the Framingham, the Reynolds Index and 
the QRISK2. In Europe, the most widely used and supported by the ESC is the 
SCORE, which calculates the risk of fatal coronary events at 10 years and stratifies the 
risk as low (<1%), moderate (≥ 1% and <5%), high (≥ 5% and <10%) and very high (≥ 
10%) (Table 3). In addition, SCORE classifies patients as they come from countries 
with high or low CV risk. The QRISK2 is the scale most commonly used in the United 
Kingdom, while the Framingham Index (Framingham Risk Score or FRS) is the 
algorithm most commonly used in the USA and Canada. Unlike SCORE, it assesses 
the risk of fatal and non-fatal coronary events also at 10 years and classifies patients as 
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Several pieces of evidence indicate that these algorithms underestimate (Framingham, 
Reynolds and SCORE) or overestimate (QRISK2) the actual CV risk in patients with 
RA [21**,107*]. For this reason, a new scale, the expanded risk score for RA (ERS-
RA), has been developed using data from the CORONA register [108*]. This scale 
incorporates specific risk factors for RA. However, the ERS-RA has also a trend to 
reclassify patients below the actual CV risk value [21**]. The application of these 
scales to other IJD is not validated yet, so their usefulness in other diseases cannot be 
estimated. 
The EULAR task force proposed a modified SCORE system as a mean of improving 
CV risk stratification [109**]. It is obtained by using a multiplication factor of 1.5 
applied to the calculated SCORE risk in patients with RA.. The updated 2015/2016 
EULAR recommendations indicate that this 1.5 multiplier factor must be applied to all 
patients with RA (other indexes such as QRISK2 multiply by 1.4) irrespective of other 
risk factors, and even then, we may fall short of the actual CV risk estimation of our 
patients with IJD [110]. However, this CVD risk calculator has not been prospectively 
evaluated in patients with RA so that its validity has not yet proven [111**]. 
For this reason, other recommendations such as the Dutch  multidisciplinary guidelines 
for the management of CV risk advise to increase systematically the age of the patient 
with RA by 10-15 years to calculate their CV risk more accurately [112]. Although the 
same could apply to AS and PsA, we do not have sufficient evidence today to extend 
the same correction factor to these two pathologies. 
The use of non-invasive imaging techniques such as carotid US enables us to classify 
and stratify more adequately the CV risk of patients with IJD. This is especially true 
for intermediate risk patients. Thus, an increased cIMT>0.90 mm or the presence of 









Unmet needs in CV management of IJD  Exp Rev Clin Immunol 
19 
 
Information Classification: General 
high or very high risk up to 63% of patients with RA previously classified as moderate 
risk by indexes [27**]. Recently, the same has been demonstrated in patients with AS 
[29]. In keeping with that, in a series of 226 patients with PsA, Eder et al. observed 
that  
56.1% of the patients in the FRS-based low to intermediate risk groups had carotid 
plaques. Interestingly, 55.9% of the patients from the FRS-based intermediate risk 
category were reclassified into an US-based high-risk category, while 47.1% of the 
patients in the FRS-based low-risk category were reclassified into a higher US-based 
risk group [113].   
Another scale of great clinical interest is the one proposed by the ACC/AHA for lipid-
lowering treatment (LLT), in which 3 main risk categories are considered: low risk 
(<5%), intermediate risk (≥5 and <7.5%) and high risk (≥7.5% and/or age between 40 
and 75 years plus DM and/or LDL-C >4.9 mmol/L and/or established CVD) [114**]. 
According to these guidelines, treatment is recommended for all high-risk patients, but 
not advised for low-risk patients, and it should be considered individually for 
intermediate-risk patients [79*,114**].  
All the data mentioned have a direct impact on the treatment of patients with IJD. 
Strictly applying CV management recommendations will prevent CVE more 
appropriately and reduce mortality in these patients (Table 3). 
2.9. Prevention and treatment of cardiovascular disease in IJD 
Based on the aforementioned risk scales, particularly on the SCORE, the European 
League Against Rheumatism (EULAR) updated in 2016 the recommendations for CV 
risk management in patients with IJD. Although these recommendations are initially 
focused on RA, due to the increasing scientific evidence available, they can also be 
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Furthermore, the EULAR task force emphasizes the relevant role of the 
rheumatologists in this strategy. Indeed, rheumatologists should coordinate the overall 
treatment strategy of CV morbidity promoting healthy lifestyle habits, such as a 
cardioprotective diet, sodium restriction, regular physical exercise, adequate sun 
exposure, weight control, avoiding overweight and insisting on toxic habits cessation, 
especially smoking [111**,115, 116**,117,118]. 
Interestingly, due to the negative effect of vitamin D deficiency on the CV system, an 
optimal intake of vitamin D and omega-3 acids (primarily from the diet) should be 
guaranteed. Besides other beneficial effects, omega-3 acids are likely to reduce CV 
risk and RA symptoms due multiple functions, including an anti-inflammatory and 
NSAIDs sparing effect [119,120]. Moderate physical activity is advisable, preferably 
aerobic, at least 2.5-5 hours per week, ideally performing at least 30 min daily.  Since 
many patients will have functional sequelae due to their underlying disease, special 
exercise programs directed by physiotherapists are suggested. 
It is also important to keep in mind that intensive dental hygiene appears to reduce the 
CV risk in general population [121-122]. However, the effects of dental hygiene on 
CV morbidity in IJDs deserves further studies. 
It is important to limit the use of potentially cardiotoxic medication, such as NSAIDs 
and GC [111**,115]. Although NSAIDs may have a lesser harmful effect in IJD than 
in the general population, due to their potential anti-inflammatory effects along with 
other potential beneficial effects in these patients such as the improvement  of  
mobility, they should be used at the lowest dose and for the shortest possible time 
[111**,123*,124]. Regarding GC, they should also be used with caution, at the lowest 
dose and for the shortest possible period of time, due to its harmful effect on the 
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medications such as leflunomide and cyclosporine A should be used with caution, 
especially in HTN patients with IJD [125]. 
Control of disease activity is a key objective as it has been associated with a reduction 
of CV mortality in patients with IJD. RA patients in remission have lower levels of 
inflammation biomarkers, lower blood pressure (BP) and better arterial compliance 
[126]. Among DMARDs, MTX use has been associated with reductions in CVD in 
several studies [127]. This evidence was stronger for the overall reduction in CV 
morbidity and mortality but weaker for stroke reduction [127].  
TNF-α inhibitors may protect against CV events in patients with RA, as shown in a 
meta-analysis of 16 cohort studies, in which the risk reductions associated with TNF-α 
blockers use were 31% for any CVE, 19% for MI and 15% for stroke [106]. The 
CORRONA registry, including 10,156 RA patients followed-up for a mean of 22.9 
months, supported this beneficial role as the risk of CVE (MI, stroke, and death) in the 
subgroup on TNF-α antagonists was lower than in the subgroup receiving MTX or 
other DMARDs [128]. Significant risk reductions were also found for nonfatal MI or 
stroke [128].  
Regarding HTN, there are no specific recommendations different from those used in 
the general population. Currently, and according to the recommendations by the ESC, 
it is advisable to maintain systolic BP (SBP) figures <140 mm Hg and diastolic BP 
(DBP) <90 mm Hg, as in the general population [92**,129**]. According to the 2017 
American HTN Guidelines [130**], the use of antihypertensive agents for primary 
intervention is recommended in patients with SBP ≥130 mmHg or DBP ≥80 mmHg 
who have increased overall atherosclerotic CVD risk, whereas the cut points are 
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Therefore, tight control of BP is recommended in patients with IJD. In fact, BP values 
<130/80 mmHg should be desirable in these patients.  
With respect to dyslipidemia, diet modification is the first step for its management. 
When this measure is unsatisfactory, lipid lowering agents should be added. Among 
them, statins represent the first line of therapy [116**,131**]. Overall, statins induce a 
major decrease in CVE risk. According to a meta-analysis of 26 randomized controlled 
trials on statins, a reduction of 40 mg/dL in LDL-C levels is associated with 20% 
decrease in CVE and a 10% decrease in mortality [132*]. In secondary prevention, the 
LDL-C reduction with statins and MI recurrence rate were not different between 
patients with or without IJD [133]. 
According to the guidelines of the ESC, different risk categories and a series of target 
levels have been established [92**]. In subjects with moderate CV risk (SCORE level 
≥1 to <5%), they recommend achieving LDL-C <115 mg/dL (3 mmol/L). In those at 
high CV risk (SCORE level ≥5 to <10%), a LDL-C goal <100 mg/dL (2.6 mmol/L) is 
recommended. Finally, in patients at very high CVD risk (SCORE ≥10%), the 
recommended LDL target is <70 mg/dL (1.8 mmol/L) or a ≥50% reduction in LDL-C 
levels versus baseline levels when the therapeutic goal cannot be reached [92**]. 
Nevertheless, these criteria have been much more stringent in the last ESC/EAS 
guidelines for the management of dyslipidemias of 2019 published online at the end of 
August this year [134**]. These guidelines established the following therapeutic 
objectives: 1) An LDL-C reduction ≥ 50% from baseline and an LDL-C goal <1.4 
mmol/L (<55 mg/dL) from baseline for secondary prevention and for primary 
prevention in patients at very-high risk.  2) An LDL-C goal <1.0 mmol/L (<40 mg/dL) 
for patients with atherosclerotic CVD who experience a second vascular event within 2 
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tolerated statin-based therapy. 3) An LDL-C reduction ≥ 50% from baseline and an 
LDL-C goal <1.8 mmol/L (<70 mg/dL) in patients at high risk. 4) An LDL-C goal 
<2.6 mmol/L (<100 mg/dL) in individuals at moderate risk, and an LDL-C goal < 3.0 
mmol/L (<116 mg/dL) in individuals at low CV risk [134**,135]. 
Despite their proved efficacy and remarkable safety, statins are not always sufficient to 
reach recommended LDL-C targets in individual patients. Based on findings in the 
general population, we recommend using ezetimibe in IJD patients when the LDL-C 
target is not reached despite maximally tolerated statin doses. Furthermore, in 
intolerant or refractory patients with high/very high CV risk, a proprotein convertase 
subtilisin/kexin 9 (PCSK9) inhibitor should be added, although the experience with 
PCSK9 inhibitors in IJDs is still limited. This should be viewed in light of recently 
reported investigations including the ODYSSEY Outcomes trial [136*]. 
IJD patients with moderate CV risk according to risk chart algorithms that are 
reclassified as having very high CV risk by a non-invasive technique (e.g., presence of 
plaques in the carotid US), LDL-C target could be similar to that for individuals with 
very high CV risk or SCORE ≥10% [137]. Regarding HDL-C, there is not enough 
scientific evidence for any figure to be considered as a therapeutic goal, although 
HDL-C <40 mg/dL (<1.0 mmol/L) in men and <45mg/dL (<1.2 mmol/L) in women 
indicates high CV risk [92**]. 
Due to the reduction of TC and cholesterol fractions levels detected during the phases 
of activity in patients with IJD, it is generally advised to measure lipid levels when the 
patient is in a stable/inactive phase. Likewise, according to the latest EULAR 
recommendations [111**], it is advisable to evaluate CV risk in patients with IJD at 
least once every 5 years in low-risk patients (in the previous guideline, the control was 
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do it more frequently, even on an annual basis, especially if there is evidence of 
progression of underlying disease or important changes in the treatment. 
The recommendations for the use of low dose aspirin in IJD patients must follow those 
proposed for the general population. In this way, low dose aspirin has only been 
recommended in patients with established CVD [92**,131**].  
Regarding vaccination, influenza epidemics are associated with an increased rate of 
CVE, and influenza vaccination in the general population appears to be a cost-effective 
CV prevention modality. This effect is probably greatest in high risk groups [138]. The 
European guidelines on CVD prevention in clinical practice recommended influenza 
vaccination in secondary CV prevention [139]. Similarly, the CV risk may also be 
reduced by pneumococcal vaccination [140]. Because IJD patients are at increased risk 
of infections due to immune dysregulation and immunosuppressive treatment, 
appropriate vaccination should be addressed, especially in high CV risk patients. 
As it has been exposed in this section, most studies and recommendations discussed in 
this section are focused on RA. Although they cannot be generalized to other IJDs, it 
seems to be reasonable to think that some of them may be extrapolated to AS and PsA 
until we have specific data on every one of these entities. 
2.10. Conclusions 
Cardiovascular disease is a frequent cause of morbidity and mortality in IJDs. The 
increase of this comorbidity is determined by classic CV risk factors linked to the 
underlying disease and the persistence of inflammation in a host with a specific genetic 
component. The development of CVE can occur early in the course of disease or after 
years of subclinical disease. Since CVD is associated with high mortality, it is 
important to stratify the CV risk adequately to identify individuals at high risk of CVE 
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secondary prevention of CVE should be strictly followed to prevent the occurrence of 
new events and reduce CV mortality. 
3. Expert opinion  
Cardiovascular disease is a common cause of morbi-mortality in IJDs. The increase of 
this comorbidity is determined by traditional CVRF, genetic factors, and other factors 
dependent on the specific underlying disease. It should be noted that some of the 
traditional risk factors, such as HTN, dyslipidemia or diabetes can remain unnoticed 
for many years in these patients. There are also other less known emergent CVRF that 
are more difficult to evaluate. Clinical manifestations in these patients are often 
atypical and can be misdiagnosed, in the case of ACS, with musculoskeletal pain 
which often causes delayed diagnosis which may aggravate the prognosis and increase 
the mortality. Currently, some imaging techniques enable us to visualize the lesions 
anatomically and to establish a CV risk assessment early in the course of disease. 
Among them, carotid-US (cUS) is the simplest, cheapest, most reliable and 
reproducible available method at this moment. US has a high sensitivity and 
specificity, and an excellent association with CVE development, especially at coronary 
and/or cerebrovascular level. 
There are several scales to assess the CV risk for a specific patient. In Europe, the most 
commonly used risk algorithm is the modified SCORE according to the 
recommendations proposed by the EULAR task force [111**], which enables us to 
classify patients as low, moderate, high or very-high risk and apply different 
preventive measures according to the specific risk obtained. However, the calculation 
of risk through the application of these scales in some patients is far from reality, 
needing the help of complementary imaging techniques. In this way, it is possible to 
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risk patients with increased cIMT or presence of carotid plaques on US should be 
considered as having high/very high risk and should be treated consequently. With 
respect to this, by using carotid US it has been possible to reclassify more than 50% of 
patients of intermediate or moderate risk as high or very high-risk patients [27**]. 
Treatment of high CV risk patients must be multidisciplinary. However, we are aware 
of the lower adherence to cardioprotective therapy of these patients [72,77,78]. For this 
reason, it is important to remark that both physicians and patients should be concerned 
about the increased risk of CVE, sometimes fatal, in these population. An additional 
measure to be performed in the follow-up of these subjects is the periodical assessment 
of renal damage by quantifying microalbuminuria and proteinuria as the result of 
atherosclerotic organ damage. 
Here, it is important to reinforce positively basic recommendations changing the 
patient´s lifestyle if necessary, advising healthy cardioprotective measures and 
frequent aerobic exercise adapted to every individual, avoiding toxic habits such as 
tobacco and alcohol. We must stimulate the patient to observe all the general 
recommendations and pharmacological measures established in the clinical guidelines 
with the final goal to reach the more suitable therapeutic objective individualized to 
every patient. 
Unfortunately, there are still many unmet needs in this field, as it is reflected in Table 
4, but it is essential to take into account that early diagnosis and management of the 
subclinical atherosclerotic disease must be a key part in the context of the routine 
clinical practice in coming years incorporating to the management imaging techniques. 
Therefore, overall CV risk assessment must be the ultimate goal to reduce the risk of 
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FIGURE LEGEND 
Figure 1. Overview showing the relationship between genetics, traditional 
cardiovascular risk factors, chronic inflammation, inactivity and emergent 
cardiovascular risk factors in the pathogenesis of the cardiovascular disease in 
inflammatory joint diseases. 
Footnotes: CV: cardiovascular; CVRFs: cardiovascular risk factors; NSAIDs: 
nonsteroidal anti-inflammatory drugs. Continuous lines indicate consistent or 
evidenced relationship; dashed lines indicate less recognized or consistent relationship. 
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TABLES 
Table 1. Advantages and disadvantages of different non-invasive imaging techniques 
used in the diagnosis of cardiovascular disease in inflammatory joint diseases.+ 






No radiation exposure 
No contrast needed 
Laborious 
Not very sensitive 
Inter-observer 
variability 












No radiation exposure 
Possible inter-
observer variability 












Less sensitive than 




 Contraindicated in 
allergic to contrast 
















Gd contraindicated if  
severe CKD  
  Contraindicated in 











 Radiation exposure 
Long scan times 
  Not widely available 
+ 
Abbreviations: ¶ Arterial stiffness assessment includes aortic pulse wave velocity and 
augmentation index. Similar techniques are: aortic distensibility and ABI (ankle-
brachial elasticity index).  
ACS: acute coronary syndrome; ACVD: atherosclerotic cardiovascular disease; CKD: 
chronic kidney disease; CV: cardiovascular; Gd: gadolinium; IJD: inflammatory joint 
diseases; (+/+++) = semi-quantitative evaluation in rheumatology.  









Unmet needs in CV management of IJD  Exp Rev Clin Immunol 
50 
 
Information Classification: General 
Table 2. Emergent factors of cardiovascular risk. 
 
Abbreviations: CV: cardiovascular 
 
  
Main emergent factors of CV risk non included in current risk assessment scales  
A) Psychological and social factors 
Socioeconomic and cultural factors 
Psychosocial factors, education level 
Major mood disturbances: depression and anxiety 
Family and/or job stress 
Physical inactivity  
B) Organic diseases 
Chronic kidney disease/renal failure 
Obstructive sleep apnea syndrome 
Diseases associated with thrombophilia 
Hypothyroidism 
Chronic obstructive pulmonary disease 
Periodontitis (not completely proved) 
C) Miscellany conditions 
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Table 3. Cardiovascular disease risk categories and recommended lipid lowering 
preventive treatment. 
Abbreviations: ACC/AHA: American College of Cardiology/American Heart Association; CV: 
cardiovascular; CVD: cardiovascular disease; DM: diabetes mellitus; FRS: Framingham 
Risk Score; IJD: Inflammatory joint diseases; LDL-C: low density lipoprotein cholesterol; 
SCORE: Systematic Coronary Risk Evaluation. 
*SCORE classifies patients differently as they come from countries with very-high, 
high, moderate or low CV risk. In IJD, in particular in patients with RA, modified 
SCORE is normally used, which is obtained by multiplying the result obtained by a 
correction factor of 1.5.  
¶
 
Overall, the THERAPEUTIC GOALS to start/continue a lowering lipid treatment in IJD 
patients by SCORE scale assessment are the following: Low risk: LDL always <130 mg/dL  
(3.4 mmol/L); Moderate risk: LDL <115 mg/dL (3 mmol/L); High risk: LDL <100 mg/dL (2.6 
mmol/L); Very-High risk: LDL <70 mg/dL (1.8 mmol/L) or reduction LDL-C levels ≥ 50% vs. 
levels before therapy. 
Modified from Semb et al. [ref. 79*].  
Lipid lowering 
intervention 
(medication)   
Cardiovascular disease risk categories 
ACC/AHA        SCORE*
¶
    Framingham Risk Score      
                (FRS) 
Treatment NO 
recommended 
Risk < 5% <1% and LDL-C <130 
mg/dL (3.4 mmol/L)  
≥ 1% and <5% and 
LDL-C <115 mg/dL  
(3 mmol/L) 
 




Risk 5 to 7.5% 
 
High risk ≥ 5% to <10% 
and LDL-C ≥ 100 
mg/dL (2.6 mmol/L)  
 
 
Risk ≥ 10% to < 20% 
Treatment  
recommended 
Risk ≥ 7.5% and/or age 
40-75 yrs + DM and/or 
LDL-C >190 mg/dL    
(4.9 mmol/L) and/or 
diagnosed CVD 
Risk ≥ 10% and LDL-C 
>70 mg/dL  
(1.8 mmol/L) and/or 
diagnosed CVD  
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Table 4. Unmet needs in cardiovascular risk evaluation in inflammatory joint diseases. 
Abbreviations: AS: ankylosing spondylitis; CV: cardiovascular; CVD: cardiovascular 
disease; CVE: cardiovascular event; CVRF: cardiovascular risk factors; GP: general 
practitioners; HF: heart failure; IJD: inflammatory joint diseases; PAD: peripheral 
arterial disease; PsA: psoriatic arthritis; RA: rheumatoid arthritis; T2T: treat to target 
strategy. 
Main unmet needs in CV risk assessment  
1) Epidemiology of CVD in IJDs 
- Evaluation of the incidence of CVD & CVE in early RA, as well as in early AS and 
PsA 
- Study of the prevalence of HF and PAD in patients with IJD, especially in AS and PsA 
2) Subclinical atherosclerosis 
-  Evaluation of the best method for early detection of subclinical atherosclerosis in 
IJDs 
3) Genetics 
- Expand the knowledge of CVD genetics in patients with IJD, especially AS and PsA 
  
4) CV risk factors 
- Potentiate campaigns for early detection of traditional CVRFs 
- Assess the real impact of mood disorders in CV risk scales in IJD patients  
- Study the possible relationship between periodontal disease and CVD in IJDs 
5) Anti-rheumatic medication and CVD 
- Design longitudinal studies to identify the incidence of long-term CVE in   
  patients with IJDs under biologics or small molecules and T2T control strategy 
- Evaluate CV safety in clinical trials testing new biologics and advanced therapies 
6) Stratification of CV risk in IJD patients 
- Long-term validation of CV risk algorithms in RA patients 
- Establish specific CV risk scores for AS and PsA 
7) Imaging 
- Design longitudinal studies to confirm the evolution of atheroma plaques and their   
impact on the reclassification of patients with IJDs 
8) Prevention and therapy of CVD 
- Improve the adherence to CV therapy of patients with IJD and CVRFs 
- Potentiate the relationship with GPs to improve the attention to these patients 
- Reinforce the interaction between different disciplines to improve monitoring and  
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fig 1 
 
